198 related articles for article (PubMed ID: 32979699)
1. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital.
Folkestad O; Wasmuth HH; Mjønes P; Fougner R; Hauso Ø; Fossmark R
Surg Oncol; 2020 Dec; 35():336-343. PubMed ID: 32979699
[TBL] [Abstract][Full Text] [Related]
2. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis.
Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study.
Snorradottir S; Asgeirsdottir A; Rögnvaldsson S; Jonasson JG; Björnsson ES
Cancer Epidemiol; 2022 Aug; 79():102197. PubMed ID: 35716441
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
6. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
7. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.
Daskalakis K; Karakatsanis A; Hessman O; Stuart HC; Welin S; Tiensuu Janson E; Öberg K; Hellman P; Norlén O; Stålberg P
JAMA Oncol; 2018 Feb; 4(2):183-189. PubMed ID: 29049611
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors.
Eriksson J; Garmo H; Hellman P; Ihre-Lundgren C
Ann Surg Oncol; 2017 May; 24(5):1214-1220. PubMed ID: 27904972
[TBL] [Abstract][Full Text] [Related]
10. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S; Chan DL; Moody L; Liu N; Fischer HD; Austin PC; Segelov E
JAMA Oncol; 2018 Apr; 4(4):583-585. PubMed ID: 29543939
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
13. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
14. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.
Kim MK; Warner RR; Roayaie S; Harpaz N; Ward SC; Itzkowitz S; Wisnivesky JP
J Clin Oncol; 2013 Oct; 31(30):3776-81. PubMed ID: 24043726
[TBL] [Abstract][Full Text] [Related]
15. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.
McGuinness MJ; Woodhouse B; Harmston C; Parker K; Kramer N; Findlay M; Print C; Merrie A; Lawrence B
ANZ J Surg; 2022 Jul; 92(7-8):1748-1753. PubMed ID: 35762209
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs.
Chen L; Zhou L; Zhang M; Shang L; Zhang P; Wang W; Fang C; Li J; Xu T; Tan H; Zhang P; Qiu M; Yu X; Jin K; Chen Y; Chen H; Lin R; Zhang Q; Shen L; Chen M; Li J; Li L; Chen J
BMC Cancer; 2017 Aug; 17(1):521. PubMed ID: 28778195
[TBL] [Abstract][Full Text] [Related]
18. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
19. Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors.
Karppinen N; Lindén R; Sintonen H; Tarkkanen M; Roine R; Heiskanen I; Matikainen N; Schalin-Jäntti C
Neuroendocrinology; 2018; 107(4):366-374. PubMed ID: 30293074
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Endoscopic Submucosal Dissection for Subepithelial Lesions Localized Within the Submucosa, Including Neuroendocrine Tumors: A Multicenter Prospective Study.
Kobara H; Miyaoka Y; Ikeda Y; Yamada T; Takata M; Fujihara S; Nishiyama N; Fujita K; Tani J; Kobayashi N; Chiyo T; Yachida T; Okano K; Suzuki Y; Mori H; Masaki T
J Gastrointestin Liver Dis; 2020 Mar; 29(1):41-49. PubMed ID: 32176758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
